EP1406631A4 - Dopamin-rezeptor-liganden und darauf beruhende therapeutische verfahren - Google Patents

Dopamin-rezeptor-liganden und darauf beruhende therapeutische verfahren

Info

Publication number
EP1406631A4
EP1406631A4 EP02744349A EP02744349A EP1406631A4 EP 1406631 A4 EP1406631 A4 EP 1406631A4 EP 02744349 A EP02744349 A EP 02744349A EP 02744349 A EP02744349 A EP 02744349A EP 1406631 A4 EP1406631 A4 EP 1406631A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic methods
receptor ligands
dopamine receptor
corresponding therapeutic
dopamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02744349A
Other languages
English (en)
French (fr)
Other versions
EP1406631A2 (de
Inventor
Shaomeng Wang
Judith Varady
Xihan Wu
Ji Min
Ke Ding
Beth Levant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Publication of EP1406631A2 publication Critical patent/EP1406631A2/de
Publication of EP1406631A4 publication Critical patent/EP1406631A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP02744349A 2001-06-13 2002-06-13 Dopamin-rezeptor-liganden und darauf beruhende therapeutische verfahren Withdrawn EP1406631A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29744501P 2001-06-13 2001-06-13
US297445P 2001-06-13
PCT/US2002/018914 WO2002100350A2 (en) 2001-06-13 2002-06-13 Dopamine receptor ligands and therapeutic methods based thereon

Publications (2)

Publication Number Publication Date
EP1406631A2 EP1406631A2 (de) 2004-04-14
EP1406631A4 true EP1406631A4 (de) 2005-03-23

Family

ID=23146337

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02744349A Withdrawn EP1406631A4 (de) 2001-06-13 2002-06-13 Dopamin-rezeptor-liganden und darauf beruhende therapeutische verfahren

Country Status (3)

Country Link
EP (1) EP1406631A4 (de)
CA (1) CA2450315A1 (de)
WO (1) WO2002100350A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10226459A1 (de) * 2002-06-13 2004-01-08 Neurobiotec Gmbh Verwendung von Dopamin-Partialagonisten zur Behandlung des Restless Legs Syndroms
EP1588704A1 (de) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamidderivate zur Behandlung des Restless-Leg-Syndroms und der Suchterkrankungen
EP1756114B1 (de) 2004-05-07 2014-11-19 Merck Sharp & Dohme Corp. Hiv-integrasehemmer
AP2975A (en) * 2008-07-16 2014-09-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
US8546377B2 (en) 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
EP2641907B1 (de) 2009-05-22 2015-01-28 AbbVie Inc. Herstellung von 5-HT-Rezeptor-Modulatoren
RU2015140748A (ru) 2010-05-21 2018-12-26 Эббви Инк. Модуляторы 5-нт рецепторов и способы их применения
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
ES2832893T3 (es) 2015-06-17 2021-06-11 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
WO2017031338A1 (en) * 2015-08-19 2017-02-23 East Carolina University Treatment and management of augmentation in restless legs syndrome
CN105418605B (zh) * 2015-11-23 2017-12-22 东南大学 一种改进的含氮三环类多巴胺d3受体配体的制备方法
US20180339996A1 (en) 2015-11-25 2018-11-29 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
WO2025194153A1 (en) 2024-03-15 2025-09-18 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647791A (en) * 1967-09-19 1972-03-07 Ciba Geigy Corp 2 3 4 4a 5 6-hexahydro - 1h - pyrazino (1 2-a) quinolines and pharmaceutical compositions containing same
WO1994020497A1 (en) * 1993-03-01 1994-09-15 Merck Sharp & Dohme Limited Pyrrolo-pyridine derivatives
WO1996004250A1 (en) * 1994-08-05 1996-02-15 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
WO1997040015A1 (en) * 1996-04-23 1997-10-30 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine d3 receptor subtype specific ligands

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH493546A (de) * 1966-10-05 1970-07-15 Ciba Geigy Verfahren zur Herstellung neuer Pyrazino (1,2-a)-chinoline
AU4547796A (en) * 1995-02-03 1996-08-21 Sankyo Company Limited Hexahydropyrazinoquinoline derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647791A (en) * 1967-09-19 1972-03-07 Ciba Geigy Corp 2 3 4 4a 5 6-hexahydro - 1h - pyrazino (1 2-a) quinolines and pharmaceutical compositions containing same
WO1994020497A1 (en) * 1993-03-01 1994-09-15 Merck Sharp & Dohme Limited Pyrrolo-pyridine derivatives
WO1996004250A1 (en) * 1994-08-05 1996-02-15 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
WO1997040015A1 (en) * 1996-04-23 1997-10-30 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine d3 receptor subtype specific ligands

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
G.B. SINGH ET AL.: "antihypertensive and cns depressant properties of 3-(gamma-p-fluorobenzoylpropyl)2,3,4,4a,5,6-hexahydro-1(h)-pyrazino(1,2-a)quinoline hydrochloride", EXPERIENTIA., vol. 29, no. 12, 15 December 1973 (1973-12-15), CHBIRKHAUSER VERLAG. BASEL., pages 1529 - 30, XP002292999 *
G.B. SINGH ET AL.: "pharmacological studies on 3-[gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a5,6,hexahydro-1h-pyrazino(1,2-a)quinoline hydrochloride", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH., vol. 28, no. 9, 1978, DEEDITIO CANTOR. AULENDORF., pages 1641 - 4, XP002293000 *
I. BOYFIELD ET AL.: "n-(substituted-phenyl)piperazines:", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 11, 1996, GB, pages 1227 - 32, XP004134859 *
V.ARUNA RAO: "agents acting on the central nervous system. XIII:", JOURNAL OF MEDICINAL CHEMISTRY., vol. 13, no. 3, 1970, USAMERICAN CHEMICAL SOCIETY. WASHINGTON., pages 516 - 22, XP002292998 *

Also Published As

Publication number Publication date
WO2002100350A3 (en) 2003-05-22
WO2002100350A2 (en) 2002-12-19
EP1406631A2 (de) 2004-04-14
CA2450315A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
NO20042154L (no) Terapeutiske isokinolinforbindelser
NO20035698L (no) 5-HT-reseptor-ligander og anvendelser derav
EP1495321A4 (de) Menschliche stoffwechselmodelle und -verfahren
NO20052914D0 (no) Terapeutiske forbindelser
DK1376922T3 (da) Krypteringsindretning
GB0314079D0 (en) Therapeutic agents
DK1233736T3 (da) Terapiapparat til punktvis stimulation
DE60334043D1 (de) Nadelvorrichtung
NO20033205L (no) Terapeutiske kromanforbindelser
EP1566197A4 (de) Iontophorese-gerät
DE60225985D1 (de) Dentaleinheit
DE50211586D1 (de) Programmgesteuerte Einheit
NO20050689L (no) Terapeutisk anvendelse
EP1547649A4 (de) Potentielle therapeutische vorrichtung
DE60330436D1 (de) Kultivierungsvorrichtung
DE60328409D1 (de) Röntgenuntersuchungsgerät
DE50202323D1 (de) Programmgesteuerte einheit
DE50214918D1 (de) Programmgesteuerte Einheit
DE50214328D1 (de) Programmgesteuerte Einheit
EP1538887A4 (de) Kultiviervorrichtung
ITBO20020101A1 (it) Riunito dentale
EP1453435A4 (de) Thermopolymer-zusammensetzung und verwandte methoden
AU2002345707A1 (en) Dopamine receptor ligands and therapeutic methods based thereon
DE60333157D1 (de) Medizinisches Gerät
ATA7922000A (de) Elektromedizinisches gerät

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07D 471/04 B

Ipc: 7C 07D 241/02 B

Ipc: 7C 07D 241/36 B

Ipc: 7A 61P 25/00 B

Ipc: 7A 61K 31/50 B

Ipc: 7A 61K 31/495 A

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEVANT, BETH

Inventor name: DING, KE

Inventor name: MIN, JI

Inventor name: WU, XIHAN

Inventor name: VARADY, JUDITH

Inventor name: WANG, SHAOMENG

A4 Supplementary search report drawn up and despatched

Effective date: 20050208

17Q First examination report despatched

Effective date: 20071017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080228